36,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
18 °P sammeln
  • Broschiertes Buch

The book opens the questions of successful medical treatment of various clinical forms of diabetes mellitus, as well as aspects of financing and patenting this problem in the USA. Diabetes Mellitus is the seventh leading cause of death in the U.S. and diabetic complications are interlaced with specific diverse microvascular and macrovascular pathologies resulted from hyperglycaemia.The society should expand prowess and patenting of biotechnology to cure disease and complications The work summarizes biological activities of patented carnosine mimetics resistant in formulations to enzymatic…mehr

Produktbeschreibung
The book opens the questions of successful medical treatment of various clinical forms of diabetes mellitus, as well as aspects of financing and patenting this problem in the USA. Diabetes Mellitus is the seventh leading cause of death in the U.S. and diabetic complications are interlaced with specific diverse microvascular and macrovascular pathologies resulted from hyperglycaemia.The society should expand prowess and patenting of biotechnology to cure disease and complications The work summarizes biological activities of patented carnosine mimetics resistant in formulations to enzymatic hydrolysis with human carnosinases that are acting as a universal form of antioxidant, deglycating and transglycating agents that inhibit sugar-mediated protein cross-linking, chelate or inactivate a number of transition metal ions (including ferrous and copper ions), possess lipid peroxidase type of activity and protection of antioxidant enzymes from inactivation.
Autorenporträt
Babizhayev, Mark
Dr. Mark Babizhayev is a bio-physicist and holds a Ph.D. in Biophysics and Pathophysiology. He has dedicated many years to scientific research.